

ACCEPT Addiction & Co-morbid Conditions: Enhancing Prevention & Therapeutics

Webex link to join from PC, Mac, iOS or Android:

https://uwmadison.webex.com/uwmadison/j.php?MTID=m6dfbe50f3c56cb4719e74b72b73ef916

Join by phone:

+1-415-655-0001 Meeting number/Access code: 120 276 9209 Password: 12345

For attendance, purposes please text the following code: <u>TEDPEV</u> to <u>608-260-7097</u>

Session Date: Friday, November 19, 2021

Didactic Topic and Presenter:

Strategies to Address Cocaine and Methamphetamine Use Disorder

Richard Rawson, PhD Department of Psychiatry Larner College of Medicine University of Vermont **Content Experts:**

Ritu Bhatnagar, MD; Lindsey Peterson, MS, CRC; Sheila M. Weix, MSN, RN, CARN

- 12:15 PM: Attendance text-in Introductions
- 12:25 PM: Case Presentation and Discussion
 - o Presenter: David Leinweber, MD
- 1 PM: Didactic Presentation
 - o Presenter: Richard Rawson, PhD
- 1:15 PM End of Session

Funding for this service was made possible by 435200-G-18-11448-285932-880 from Wisconsin Department of Health Services. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government or the State of Wisconsin.





CONTINUING EDUCATION INFORMATION:

Accreditation Statement



In support of improving patient care, the University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

INTERPROFESSIONAL CONTINUING EDUCATION

Accreditation Council for Pharmacy Education (ACPE)

The University of Wisconsin-Madison ICEP designates this live activity for a maximum of 1 hour of knowledge-based CE credit. Credit can be earned by successfully completing this live activity. Pharmacists and Pharmacy Technicians should claim only the credit commensurate with the extent of their participation in the activity. CE credit information, based on verification of live attendance, will be provided to NABP within 60 days after the activity completion.

Pharmacists and Pharmacy Technicians must enter their NABP number in their profile in order to receive credit.

2021 Universal Activity Number (UAN) JA0000358-9999-21-065-L01-P

American Medical Association (AMA)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 AMA PRA Category 1 Credit[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 ANCC contact hour.

UW Continuing Education Credits

The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.1 CEUs or 1.0 hour

POLICY ON FACULTY AND SPONSOR DISCLOSURE

It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education (CE). In addition, speakers, presenters and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation. For this accredited continuing education activity, all relevant financial relationships have been mitigated and detailed disclosures are listed below.

* Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.





ECHO ACCEPT Addiction & Co-morbid Conditions: Enhancing Prevention & Therapeutics 2020-2022 Strategies to Address Cocaine and Methamphetamine Use Disorder 11/19/2021 Didactic Presenter: Richard Rawson, PhD Case Presenter: David Leinweber, MD

Provided by the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP)

Intended Audience:

Nurses, Nurse Practitioners, Pharmacists, Physicians, Physician Assistants, Pharmacy Technicians, Psychologists, Social Workers, Patient/Caregivers, Students

Objectives:

As a result of this educational regularly scheduled series, learners as members of the healthcare team will be able to:

- 1. Explain the current epidemiology of cocaine and methamphetamine in the US
- 2. List the most common clinical challenges in treatment people with stimulant use disorders.
- 3. Explain the current evidence-based practices for the treatment of individuals with stimulant use disorder.

Policy on Disclosure

It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education (CE). In addition, speakers, presenters and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation. For this accredited continuing education activity, all relevant financial relationships have been mitigated and detailed disclosures are listed below.

* Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

Name	Role	Financial Relationship Disclosures	Discussion of Unlabeled/Unapproved uses of drugs/devices in presentation?	COI completion date	
Randall Brown	RSS Chair	No relevant financial relationships to disclose	Yes	3/11/21	
Nada Rashid RSS Coordinator No relevant financial relationships to disclose		No	3/11/21		
Kathleen Maher	Kathleen Maher Planner No relevant financial relationships to disclose		No	3/15/21	
Ritu Bhatnagar	Planner	No relevant financial relationships to disclose	Yes	3/12/21	
Paul Hutson	Planner	No relevant financial relationships to disclose	Yes	3/11/21	
Susan Mindock Planner No relevant financial relationships to disclose		No	3/11/21		
Lindsey Peterson	sey Peterson Planner No relevant financial relationships to disclose		No	3/11/21	
Sheila Weix,	Planner	No relevant financial relationships to disclose	No	3/11/21	
Kellene Eagen	Planner	No relevant financial relationships to disclose	No	6/23/21	

Joseph Galey	Planner	No relevant financial relationships to disclose	Yes	6/23/21
Richard Rawson	Presenter	No relevant financial relationships to disclose	No	11/8/2021
David Leinweber	Presenter	No relevant financial relationships to disclose	No	11/10/2021

Accreditation Statement



In support of improving patient care, the University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statements

The University of Wisconsin-Madison ICEP designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 ANCC contact hour(s).

The University of Wisconsin–Madison ICEP designates this knowledge-based activity for a maximum of 1 hour of CE credit. Credit can be earned by successfully completing the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. UAN: 2021 Universal Activity Number (UAN) JA0000358-9999-21-065-L01-P

The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.1 CEUs or 1 hour.



Case Presentation

David Leinweber University of Wisocnsin Department of Eamily Medicine and Community Health

Funding for this service was made possible by 435200-G-18-11448-285932-880 from Wisconsin Department of Health Services. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government or the State of Wisconsin.



Credit Designation Statements

Accreditation Council for Pharmacy Education (ACPE)

The University of Wisconsin-Madison ICEP designates this live activity for a maximum of 1 hour of knowledge-based CE credit. Credit can be earned by successfully completing this live activity. Pharmacists and Pharmacy Technicians should claim only the credit commensurate with the extent of their participation in the activity. CE credit information, based on verification of live attendance, will be provided to NABP within 60 days after the activity completion.

In support of improving patient care, the University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the

American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Pharmacists and Pharmacy Technicians must enter their NABP number in their profile in order to receive credit. 2021 Universal Activity Number (UAN) JA0000358-9999-21-065-L01-P

American Medical Association (AMA)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 AMA PRA Category 1 Credit[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC) The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 ANCC contact hour.

UW Continuing Education Credits The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.1 CEUs or 1.0 hour

Accreditation Statement:

POLICY ON FACULTY AND SPONSOR DISCLOSURE

It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education (CE). In addition, speakers, presenters and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation. For this accredited continuing education activity, all relevant financial relationships have been mitigated and detailed disclosures are listed below.

* Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

For this educational activity there are no reported conflicts of interest



Case Introduction

- One-liner (including age/sex):
 - 24 y/o male with pmh of methamphetamine use disorder severe, cocaine use, marijuana use, HIV who presents for follow up of his methamphetamine induced psychosis

- Primary question for discussion:
 - What is your approach to methamphetamine induced psychosis in the outpatient setting?



Medical & Behavioral Health Diagnosis:			Current Medications:		
• • •	Methamphetamine use disorder severe Cocaine use Marijuana use HIV Anxiety	•	Risperidone – 3.5 mg HS and 0.5 mg BID PRN Prazosin 2 mg HS Biktarvy (Bictergravir-Emtricitab-Tenofov)		



Alcohol

- Reports occasional alcohol use "a beer every now and then"
- Denies history of complicated withdrawals
- Per chart review recently stated using 1 pint of vodka daily
- First use was age 12 y/o
- Per chart review has been trialed on naltrexone within the last year but is not currently using

Methamphetamine

- First use January of 2020
- Recreational use at parties. Per chart review initial use was with brother and sister.
- Uses by inhalation and injection. Prefers to use by injection per chart review.
- At current visit states he would not like speak about if he is currently using or last use of methamphetamine
- Longest period of abstinence from methamphetamine per chart review 14 days
- Cocaine
 - Intermittent use by insufflation. States use is intermittent due to cost
 - First use July of 2020

Marijuana use

- First use age 13 y/o
- Daily use by inhalation
- Tobacco Use 1-2 PPD
- Dextromethorphan/Chlorphenamine (Coricidin)
 - History of use as teenager
 - Per chart review had overdose due to dextromethorphan/chlorphenamine at age 16 y/o
- Hallucinogen history of use
- Opiates denies
- Benzodiazepines denies



- Consequences of Substance Use:
 - Social/occupational/educational:
 - Suicide attempt May of 2021 in setting of methamphetamine induced psychosis
 - Age 15 y/o was involved in a robbery in setting of alcohol intoxication. Led to being court ordered to adolescent residential center.
 - Currently unemployed due to inability to work due to methamphetamine induced psychosis
 - Physical (including evidence of tolerance/withdrawal):
 - Methamphetamine Induced Psychosis. Endorses visual and auditory hallucinations
 - Visual Hallucinations described as "negative". Refuses to describe visual hallucinations.
 - Auditory Hallucinations described at visit as "negative" and constant. When asked further states he would not like to say what voices are saying. When asked directly if voices are telling him to hurt himself he nods.
 - Denies having hallucinations prior to use of methamphetamine
 - First noted from chart review on 10/2020
 - Suicide Attempt in May of 2021 led to forearm injury from laceration. This has led to hand weakness which led to loss of factory job he had due to hand weakness
 - Incarcerated for past month for unknown reasons. During incarceration states he was not able to take his risperidone which led to increased hallucinations.



Past treatments:

- risperidone 3.5 mg HS and 0.5 mg BID PRN patient notes he continued to hallucinate while at this dose prior to incarceration. Note risperidone not taken past month during incarceration
- Prazosin 2 mg HS (for nightmares)
- Olanzapine
- Gabapentin
- Naltrexone
- Zoloft
- Seroquel



Social History

- Social Factors/History: housing unstable
- Family History: denies family history of psychiatric conditions, endorses family history of substance use
- Education/Literacy: completed high school
- Income source: unemployed



Patient strengths & protective factors:	Risk factors:
 Engaged in outpatient mental health treatment Engaged in substance use treatment Denies having made preparatory acts based on command auditory hallucinations States he feels "safe" and denies having plans or acts to harm himself or others Endorses that risperidone in the past has helped with hallucinations Endorses that prazosin in the past has improved nightmares 	 Housing Unstable Unemployed History of suicide attempt Little support system Family History of substance use

ECHO[®]

University of Wisconsin

Labs

Last Urine Drug Screen: May 2021

- Amphetamines positive
- Barbiturates negative
- Benzodiazepine negative
- Cocaine Metabolite negative
- Opiates negative
- Phencyclidine negative
- Cannabinoids negative
- HIV RNA <30 June 2021</p>



Patient Goals & Motivations for Treatment

 Patient would like to restart risperidone and prazosin as he has not used in past month. Hope is to decrease auditory and visual hallucinations as well as nightmares.



Proposed Diagnoses

- Methamphetamine induced psychosis
- Did consider



Proposed Treatment Plan

- 4 mg risperidone HS and 0.5 mg BID PRN
- Prazosin 2 mg HS
- Follow up in 1 week
- Offered inpatient psychiatric admission which patient declined.
- Created safety plan with patient regarding when to present to emergency department



Discussion:

Primary question: What is your approach to methamphetamine induced psychosis in the outpatient setting?



DSM-5 Substance Use Disorder ("Addiction")

- Physical Dependence ≠ Use Disorder
- ToleranceWithdrawal
- Larger amts/longer periods than intended
- Persistent desire/failed attempts to quit/control use
- Much time obtaining/using/recovering
- Important activities sacrificed
- Continued use despite known adverse effects
- Failure to fulfill major obligations
- Recurrent hazardous use
- Craving
- Ongoing use despite interpersonal problems

By initialing here DQL you have acknowledged that Project ECHO case consultations do not create or otherwise establish a provider-patient relationship between any ECHO clinician and any patient whose case is being presented in a teleECHO clinic.

2 - 3 = mild

 $\geq 6 = severe$

4-5 = moderate



Strategies to Address Cocaine and Methamphetamine Use Disorder

Richard Rawson, PhD Department of Psychiatry Larner College of Medicine University of Vermont

Funding for this service was made possible by 435200-G-18-11448-285932-880 from Wisconsin Department of Health Services. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government or the State of Wisconsin.



Credit Designation Statements

Accreditation Council for Pharmacy Education (ACPE)

The University of Wisconsin-Madison ICEP designates this live activity for a maximum of 1 hour of knowledge-based CE credit. Credit can be earned by successfully completing this live activity. Pharmacists and Pharmacy Technicians should claim only the credit commensurate with the extent of their participation in the activity. CE credit information, based on verification of live attendance, will be provided to NABP within 60 days after the activity completion.

In support of improving patient care, the University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the

American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Pharmacists and Pharmacy Technicians must enter their NABP number in their profile in order to receive credit. 2021 Universal Activity Number (UAN) JA0000358-9999-21-065-L01-P

American Medical Association (AMA)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 AMA PRA Category 1 Credit[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC) The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 ANCC contact hour.

UW Continuing Education Credits The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.1 CEUs or 1.0 hour

Accreditation Statement:

POLICY ON FACULTY AND SPONSOR DISCLOSURE

It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education (CE). In addition, speakers, presenters and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation. For this accredited continuing education activity, all relevant financial relationships have been mitigated and detailed disclosures are listed below.


* Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

For this educational activity there are no reported conflicts of interest



Center on Rural Addiction UNIVERSITY OF VERMONT

Evolution of Drivers of Overdose Deaths, All Ages



Source: The Multiple Cause of Death data are produced by the Division of Vital Statistics, National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), United States Department of Health and Human Services (US DHHS).

4



Clinical Challenges



Clinical Challenges for Individuals with Methamphetamine Use Disorder

Overdose death

Limited understanding of stimulant addiction Ambivalence about need to stop use Impulsivity/Poor judgement Cognitive impairment and poor memory

Paranoia



Clinical Challenges with Individuals with Methamphetamine Use Disorder

Anhedonia Hypersexuality/Hyposexuality Violence and psychosis Powerful Pavlovian trigger-craving response Very poor retention in outpatient treatment



Special Treatment Consideration Should Be Made for the Following Groups

People who inject methamphetamine.

People who use methamphetamine daily.

Women (high rates of physical/sexual abuse).

Homeless, chronically mentally ill and/or individuals with high levels of psychiatric symptoms at admission.

Men who have sex with men (MSM).

People who use stimulants who are under the age of 21.

Individuals in medication treatment for OUD.



Interest in Reducing Methamphetamine and Opioid Use among Syringe Services Program Participants in Washington State McMahan et al, 2020 Drug and Alcohol Dependence

- In a sample of 583 participants at a Washington State syringe exchange program (443 opioids; 140 methamphetamine), survey data were collected on their attitudes about stopping drug use.
- <u>82% of the individuals who reported opioids</u> as their main drug expressed an interest in reducing/stopping opioid use
- <u>46% of individuals who reported methamphetamine</u> as their main drug expressed an interest in reducing/stopping their meth use.



Treatment for Individuals with Stimulant Use Disorder



DO NO HARM

- FOR PATIENTS IN TREATMENT FOR OUD WITH METHADONE OR BUPRENORPHINE, KICKING PEOPLE OUT OF TREATMENT FOR STIMULANT USE DRAMATICALLY INCREASES THEIR RISK OF DEATH BECAUSE OF THE PERVASIVE PRESENCE OF FENTANYL IN THE DRUG SUPPLY.
- WHEN PEOPLE ARE KICKED OUT OF MOUD TREATMENT IN 2021, THEY DON'T GET BETTER, THEY GET DEAD.



- Information about medical and psychiatric effects of meth
- Overdose education (fentanyl)
- Syringe exchanges
- Naloxone (for opioid overdose)
- Quiet rooms and wash up/shower rooms
- Condoms/safe sex education
- Topical antibiotic creams and ointments for injection sites
- Water (dehydration)
- Toothpaste/toothbrush



Current Status of Treatment Approaches for Stimulant Use Disorder

- Contingency management unanimously (7 recent systematic reviews and meta-analyses) found to have best evidence of effectiveness.
- Other approaches with lesser but evidence of support: <u>Cognitive Behavioral Therapy (CBT)</u> and <u>Community Reinforcement Approach (CRA)</u>
- Approach with recent studies showing benefit to methamphetamine users: <u>Physical Exercise (PE).</u> (eg. Rawson et al, 2015)



Non-pharmacological interventions for methamphetamine use disorder: a systematic review Drug and Alcohol Dependence, AshaRani, PV, et al. 2020

- 44 Studies reviewed.
- Conclusions: While <u>Contingency Management (CM)</u> <u>interventions showed the strongest evidence</u> favoring the outcomes assessed, tailored CBT alone or with CM was also effective in the target population.



Bentzley BS, Han SS, Neuner S, Humphreys K, Kampman KM, Halpern CH. Comparison of Treatments for Cocaine Use Disorder Among Adults: A Systematic Review and Meta-analysis. *JAMA Netw Open.* 2021;4(5):e218049. doi:10.1001/jamanetworkopen.2021.8049



Results A total of 157 studies comprising 402 treatment groups and 15 842 participants were included.

Only contingency management programs were significantly associated with an increased likelihood of having a negative test result for the presence of cocaine (OR, 2.13; 95%)

Conclusions In this meta-analysis, <u>contingency management</u> <u>programs were associated with reductions in cocaine use</u> <u>among adults</u>.



Bolivar, H.A., Klemperer, E.M., Coleman, S.R., Skelly, J., Higgins, S.T. Contingency Management for Patients Receiving Medication for Opioid Use Disorder: A Systematic Review and Meta-analysis. *JAMA Psychiatry.* Published online August 4, 2021. doi:10.1001/jamapsychiatry.2021.1969



These results provide evidence supporting the use of contingency management in addressing key clinical problems among patients receiving MOUD, including the ongoing epidemic of comorbid psychomotor stimulant misuse.



Chan B, Freeman M, Ayers C, Korthuis PT, Paynter R, Kondo K, Kansagara D. A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders. Drug Alcohol Depend. 2020 Nov 1;216:108193. doi: 10.1016/j.drugalcdep.2020.108193. Epub 2020 Aug 1. PMID: 32861136.



- An examination of multiple classes of medications used for the treatment of cocaine and methamphetamine use disorders in people with OUD found <u>no strong evidence that</u> <u>any medication was effective in increasing abstinence,</u> reducing use, or improving retention.
- There is almost no evidence regarding treatment of methamphetamine use disorder in people with OUD.
- Antidepressants and disulfiram may worsen treatment outcomes when used for treatment of cocaine use disorders in patients with OUD.



Contingency Management

A technique employing the <u>systematic delivery of</u> <u>positive reinforcement for desired behaviors</u>. In the treatment of methamphetamine dependence, vouchers or prizes can be "earned" for submission of methamphetamine-free urine samples.





Learning occurs best when the behavior is followed immediately by the consequence.



Basic Behavioral Principles

- **1. Frequently monitor target behavior**
- 2. Provide incentive when target behavior occurs
- 3. Remove incentive when target behavior does not occur





A common protocol for using CM is to provide reinforcers (rewards, incentives) for stimulant negative urine samples.



The American Journal on Addictions, 23: 205–210, 2014 Copyright © American Academy of Addiction Psychiatry ISSN: 1055-0496 print / 1521-0391 online DOI: 10.1111/j.1521-0391.2014.12092.x

Nationwide Dissemination of Contingency Management: The Veterans Administration Initiative

Nancy M. Petry, PhD,¹ Dominick DePhilippis, PhD,² Carla J. Rash, PhD,¹ Michelle Drapkin, PhD,² James R. McKay, PhD²

¹University of Connecticut School of Medicine, Farmington, Connecticut ²Dept of Veterans Affairs and University of Pennsylvania, Philadelphia, Pennsylvania



Stay Connected

Vermont Center on Behavior and Health (VCBH)

- Follow Twitter: <u>@vtcenterbh</u>
- Like Facebook: @<u>vtcenterbh</u>
- Follow LinkedIn: <u>linkedin.com/company/vermont-center-on-behavior-and-health</u>
- Subscribe YouTube: <u>youtube.com/channel/UCgTdhdZb7GAu8f12EhjcN3g</u>
- Website: <u>http://www.med.uvm.edu/behaviorandhealth/home</u>
- Contact Us: <u>VCBH@uvm.edu</u>

rrawson@uvm.edu

Center on Rural Addiction (CORA)

- Follow Twitter: @<u>uvmcora</u>
- Website: <u>uvmcora.org</u>
- Contact Us: <u>CORA@uvm.edu</u>



DSM-5 Substance Use Disorder ("Addiction")

- Tolerance
- Physical Dependence \neq Use Disorder
- Withdrawal
- Larger amts/longer periods than intended
- Persistent desire/failed attempts to quit/control use
- Much time obtaining/using/recovering
- Important activities sacrificed
- Continued use despite known adverse effects
- Failure to fulfill major obligations
- Recurrent hazardous use
- Craving
- Ongoing use despite interpersonal problems
- 2-3 = mild4-5 = moderate $\ge 6 = severe$

